We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Novo Nordisk | NYSE:NVO | NYSE | Common Stock |
Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|
0.0789 | 0.07% | 118.2989 | 118.265 | 117.14 | 117.70 | 3,193,443 | 01:00:00 |
MISSISSAUGA, ON, July 24, 2015 /CNW/ - Mr. Jakob Riis, Executive Vice President, China, Pacific & Marketing, Novo Nordisk A/S, is pleased to announce the appointment of Mr. Brian Hilberdink to the role of President, Novo Nordisk Canada Inc.
Mr. Hilberdink is an accomplished executive with 20 years of global and domestic experience developing and executing Novo Nordisk's commercial strategy. He previously held the position of Vice President, Diabetes Marketing and Market Access, Novo Nordisk Canada. Prior to this role, Brian was Corporate Vice President, Global Marketing, Novo Nordisk A/S, and led the commercialization of the company's future insulin portfolio, from phase 2 clinical development until the first launches in Europe and Japan. He also has experience working in the U.S. where, as Director, Brand Management, he led multiple brand teams during a period of significant growth for Novo Nordisk U.S.
"I'm truly honoured to be part of an organization that has played a central role in helping to defeat diabetes and other serious chronic conditions, such as hemophilia, growth disorders and obesity," said Brian Hilberdink, President, Novo Nordisk Canada. "Moving forward, I am excited about the opportunity to have an even greater impact in Canada through the development of strong partnerships and the offering of new products and services to best support patients, their families and healthcare professionals."
About Novo Nordisk
Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat other serious chronic conditions: hemophilia, growth disorders and obesity. Headquartered in Denmark, Novo Nordisk employs approximately 39,000 people in 75 countries and markets its products in more than 180 countries. For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube
SOURCE Novo Nordisk Canada Inc.
Copyright 2015 Canada NewsWire
1 Year Novo Nordisk Chart |
1 Month Novo Nordisk Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions